The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods

İstanbullu Hüseyin; Turunc Ezgi; Hamdoun Sami; Saylam Merve; Koyu Halil; Kaya Temiz Tĳen

doi:https://dx.doi.org/10.26650/IstanbulJPharm.2023.1269175

Research Article

DOI :10.26650/IstanbulJPharm.2023.1269175 IUP :10.26650/IstanbulJPharm.2023.1269175 Full Text (PDF)

The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods

Hüseyin İstanbullu, Ezgi Turunc, Sami Hamdoun, Merve Saylam, Halil Koyu, Tĳen Kaya Temiz

Background and Aims:Histone deacetylases (HDACs) modulate chromatin structure and regulate gene expression. The imbalance in chromatin acetylation and dysregulation of histone deacetylases are challenging in many pathologies, ranging from cancer to neurodegeneration. Computer-based in silico methods are becoming increasingly important in the determination of therapeutic targets and the development of personalized treatment approaches. This study aimed to investigate the HDAC1 inhibitory effects of chronic prescription drugs using in silico and in vitro methods.

Methods:Five chronically used prescription drugs were chosen: ipratropium bromide, metoprolol, leflunomide, nateglinide, and levothyroxine. Molecular docking was performed for each of the chosen drugs as well as the known inhibitor Trichostatin A on HDAC1. The binding pose with the best scores was saved for each compound and analyzed for its interaction with the protein. An HDAC1 inhibitor screening assay kit was used to determine the IC50 value for each drug.

Results:The IC50 values for HDAC1 inhibition by ipratropium bromide, metoprolol, leflunomide, nateglinide, and levothyroxine were found to be 352.10 μM, 255.70 μM, 219.80 μM, 289.50 μM, and 132.70 μM, respectively, whereas the value for the positive control Trichostatin A was 36.13 nM. GraphPad Prism 5 was used to conduct statistical analyses.

Conclusion:In this study, the in vitro HDAC1 inhibitory effect of ipratropium bromide, metoprolol, leflunomide, nateglinide, and levothyroxine is shown for the first time. In silico and in vitro methodologies used to show HDAC1 inhibitory activity in marketed drugs can provide insight into new drug discovery studies against cancer or neurodegenerative diseases.

Keywords: Docking, drug repurposing, HDAC1, in silico, molecular modeling

References

Bahari-Javan, S., Varbanov, H., Halder, R., Benito, E., Kaurani, L., Burkhardt, S.... Fischer, A. (2017). HDAC1 links early life google scholar
stress to schizophrenia-like phenotypes. Proceedings of the Na-tional Academy of Sciences of the USA, 6;114(23):E4686-E4694. https://doi.org/10.1073/pnas.1613842114 google scholar
Boyd, A. S. (2012). Leflunomide in dermatology. Journal of the American Academy of Dermatology, 66(4):673-679. https://doi.org/10.1016/j.jaad.2011.08.025 google scholar
Cacabelos, R., Torrellas, C. (2014). Epigenetic drug discovery for Alzheimer’s disease. Expert Opinion Drug Discovery, 9(9):1059-1086. https://doi.org/10.1517/17460441.2014.930124 google scholar
Cordeiro, A., de Souza, L. L., Oliveira, L. S., Faustino, L. C., Santiago, L. A., Bloise, F. F.... Pazos-Moura, C. C. (2013). Thyroid google scholar
hormone regulation of Sirtuin 1 expression and implications to integrated responses in fasted mice. Journal of Endocrinology, 216(2):181-193. https://doi.org/10.1530/JOE-12-0420 google scholar
Dovey, O. M., Foster, C. T., Cowley, S. M. (2010). His-tone deacetylase 1 (HDAC1), but not HDAC2, controls em-bryonic stem cell differentiation. Proceedings of the Na-tional Academy of Sciences of the USA, 107(18):8242-8247. https://doi.org/10.1073/pnas.100047810 google scholar
Ganai, S. A., Abdullah, E., Rashid, R., Altaf, M. (2017). Com-binatorial In Silico Strategy towards Identifying Potential Hotspots during Inhibition of Structurally Identical HDAC1 and HDAC2 Enzymes for Effective Chemotherapy against Neurolog-ical Disorders. Frontiers in Molecular Neurosciences, 10:357. https://doi.org/10.3389/fnmol.2017.00357 google scholar
Gao, Q., Yao, P., Wang, Y., Yao, Q., Zhang, J. (2022). Discovery of potent HDAC2 inhibitors based on virtual screening in combi-nation with drug repurposing. Journal of Molecular Structure, 1247(5):131399. https://doi.org/10.1016/j.molstruc.2021.131399 google scholar
Grassi, G. (2018). Metoprolol in the treatment of car-diovascular disease: a critical reappraisal. Current Medical Research and Opinion, 34(9):1635-1643. https://doi.org/10.1080/03007995.2018.1479245 google scholar
Guan, M., Fousek, K., Chow, W.A. (2012). Nelfinavir inhibits regu-lated intramembrane proteolysis of sterol regulatory element bind-ing protein-1 and activating transcription factor 6 in castration-resistant prostate cancer. The FEBS Journal, 279(13):2399-2411. https://doi.org/10.1111/j.1742-4658.2012.08619.x google scholar
Halas, C. J. (2001). Nateglinide. American Jour-nal of Health System Pharmacy, 58(13):1200-1205 https://doi.org/10.1093/ajhp/58.13.1200 google scholar
Hirata, Y., Sasaki, T., Kanki, H., Choong, C. J., Nishiyama, K., Kubo, G.... Uesato S. (2018). New 5-Aryl-Substituted 2- google scholar
Aminobenzamide-Type HDAC Inhibitors with a Diketopiper-azine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death. Scientific Reports, 8(1):1400. https://doi.org/10.1038/s41598-018-19664-9 google scholar
laniro, G., Mangiola, F., Di Rienzo, T.A., Bibbo, S., Franceschi, F., Greco, A.V., Gasbarrini, A. (2014). Levothyroxine absorption in health and disease, and new therapeutic perspectives. European Review for Medical and Pharmacological Sciences, 18(4):451-456. google scholar
Johnstone, R.W. (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Reviews Drug Discovery, 1(4):287-299. https://doi.org/10.1038/nrd772 google scholar
Kazi, A. A., Reddy, B. V. S., Singh, L. R. (2021). Synthetic ap-proaches to FDA approved drugs for asthma and COPD from 1969 to 2020. Bioorganic & Medicinal Chemistry 41:116212. https://doi.org/10.1016/j.bmc.2021.116212 google scholar
Kitchen, D.B., Decornez, H., Furr, J. R., Bajorath, J. (2004). Dock-ing and scoring in virtual screening for drug discovery: methods and applications. Nature Reviews Drug Discovery, 3(11):935-949. https://doi.org/10.1038/nrd1549 google scholar
Lardenoije, R., latrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D.... Rutten, B. P. F. (2015). The epigenetics of aging and neurodegeneration. Progress in Neurobiology, 131:21-64. https://doi.org/10.1016/j.pneurobio.2015.05.002 google scholar
Li, Q., Huang, K., Ma, T., Lu, S., Tang, S., Wu, M., Yang, H., Zhong, J. (2022). Metoprolol Protects Against Arginine Vasopressin-Induced Cellular Senescence in H9C2 Cardiomyocytes by Reg-ulating the Sirt1/p53/p21 Axis. Cardiovascular Toxicology, 22(2):99-107. https://doi.org/10.1007/s12012-021-09704-8 google scholar
Li, Y.Y., Jones, S. J. (2012). Drug repositioning for personalized medicine. Genome Medicine, 4(3):27. https://doi.org/10.1186/gm326 google scholar
Lindemann, R. K., Gabrielli, B., Johnstone, R.W. (2004). Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle, 3(6):777-786. https://doi.org/10.4161/cc.3.6.927 google scholar
Lindemann, R. K., Gabrielli, B., Johnstone, R.W. (2004). Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle, 3(6):777-786. https://doi.org/10.4161/cc.3.6.927 google scholar
Müller, B. M., Jana, L., Kasajima, A., Lehmann, A., Prinzler, J., Budczies, J.... Denkert, C. (2013). Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clin-icopathological indicators of disease progression. BMC Cancer, 13:215. https://doi.org/10.1186/1471-2407-13-215 google scholar
Park, H., Kim, S., Kim, Y.E., Lim, S.J. (2010). A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promis-ing zinc-chelating groups. ChemMedChem., 5(4):591-597. https://doi.org/10.1002/cmdc.200900500 google scholar
Park, S. Y., Kim, J. S. (2020). A short guide to his-tone deacetylases including recent progress on class II en-zymes. Experimental & Molecular Medicine, 52(2):204-212. https://doi.org/10.1038/s12276-020-0382-4 google scholar
Pushpakom, S., Iorio, F., Eyers, P.A., Escott, K.J., Hopper, S., Wells, A.... Pirmohamed, M. (2019). Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery, 18(1):41-58. https://doi.org/10.1038/nrd.2018.168 google scholar
Serebryannyy, L.A., Cruz, C.M., de Lanerolle, P. (2016). A Role for Nuclear Actin in HDAC 1 and 2 Regulation. Scientific Reports, 6:28460. https://doi.org/10.1038/srep28460 google scholar
Spiegel, S., Milstien, S., Grant, S. (2012). Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene. 31(5):537-551. https://doi.org/10.1038/onc.2011.267 google scholar
Taunton, J., Hassig, C.A., Schreiber, S. L. (1996). A mam-malian histone deacetylase related to the yeast tran-scriptional regulator Rpd3p. Science. 272(5260):408-411. https://doi.org/10.1126/science.272.5260.408 google scholar
Vishwakarma, S., Iyer, L.R., Muley, M., Singh, P.K., Shastry, A., Saxena, A., Narayanan, S. (2013). Tubastatin, a selective his-tone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects. International Immunopharmacology, 16(1):72-78. https://doi.org/10.1016/j.intimp.2013.03.016 google scholar
Wang, J., Yu, J.T., Tan, M.S., Jiang, T., Tan, L. (2013). Epigenetic mechanisms in Alzheimer’s disease: implications for pathogen-esis and therapy. Ageing Research Reviews, 12(4):1024-1041. https://doi.org/10.1016/j.arr.2013.05.003 google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format

EXPORT

APA

İstanbullu, H., Turunc, E., Hamdoun, S., Saylam, M., Koyu, H., & Kaya Temiz, T. (2023). The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods. İstanbul Journal of Pharmacy, 53(3), 287-293. https://doi.org/10.26650/IstanbulJPharm.2023.1269175

AMA

İstanbullu H, Turunc E, Hamdoun S, Saylam M, Koyu H, Kaya Temiz T. The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods. İstanbul Journal of Pharmacy. 2023;53(3):287-293. https://doi.org/10.26650/IstanbulJPharm.2023.1269175

ABNT

İstanbullu, H.; Turunc, E.; Hamdoun, S.; Saylam, M.; Koyu, H.; Kaya Temiz, T. The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods. İstanbul Journal of Pharmacy, [Publisher Location], v. 53, n. 3, p. 287-293, 2023.

Chicago: Author-Date Style

İstanbullu, Hüseyin, and Ezgi Turunc and Sami Hamdoun and Merve Saylam and Halil Koyu and Tĳen Kaya Temiz. 2023. “The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods.” İstanbul Journal of Pharmacy 53, no. 3: 287-293. https://doi.org/10.26650/IstanbulJPharm.2023.1269175

Chicago: Humanities Style

İstanbullu, Hüseyin, and Ezgi Turunc and Sami Hamdoun and Merve Saylam and Halil Koyu and Tĳen Kaya Temiz. “The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods.” İstanbul Journal of Pharmacy 53, no. 3 (Apr. 2024): 287-293. https://doi.org/10.26650/IstanbulJPharm.2023.1269175

Harvard: Australian Style

İstanbullu, H & Turunc, E & Hamdoun, S & Saylam, M & Koyu, H & Kaya Temiz, T 2023, 'The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods', İstanbul Journal of Pharmacy, vol. 53, no. 3, pp. 287-293, viewed 28 Apr. 2024, https://doi.org/10.26650/IstanbulJPharm.2023.1269175

Harvard: Author-Date Style

İstanbullu, H. and Turunc, E. and Hamdoun, S. and Saylam, M. and Koyu, H. and Kaya Temiz, T. (2023) ‘The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods’, İstanbul Journal of Pharmacy, 53(3), pp. 287-293. https://doi.org/10.26650/IstanbulJPharm.2023.1269175 (28 Apr. 2024).

MLA

İstanbullu, Hüseyin, and Ezgi Turunc and Sami Hamdoun and Merve Saylam and Halil Koyu and Tĳen Kaya Temiz. “The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods.” İstanbul Journal of Pharmacy, vol. 53, no. 3, 2023, pp. 287-293. [Database Container], https://doi.org/10.26650/IstanbulJPharm.2023.1269175

Vancouver

İstanbullu H, Turunc E, Hamdoun S, Saylam M, Koyu H, Kaya Temiz T. The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods. İstanbul Journal of Pharmacy [Internet]. 28 Apr. 2024 [cited 28 Apr. 2024];53(3):287-293. Available from: https://doi.org/10.26650/IstanbulJPharm.2023.1269175 doi: 10.26650/IstanbulJPharm.2023.1269175

ISNAD

İstanbullu, Hüseyin - Turunc, Ezgi - Hamdoun, Sami - Saylam, Merve - Koyu, Halil - Kaya Temiz, Tĳen. “The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods”. İstanbul Journal of Pharmacy 53/3 (Apr. 2024): 287-293. https://doi.org/10.26650/IstanbulJPharm.2023.1269175

Volume 53, Issue 32023, P. 287-293

TIMELINE

Submitted	23.03.2023
Accepted	25.09.2023
Published Online	28.11.2023

LICENCE

Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.

İstanbul Journal of Pharmacy

Research Article

The investigation of drug repurposing for HDAC1 inhibitory effects by in silico and in vitro methods

PDF View

References

Citations

EXPORT

APA

AMA

ABNT

Chicago: Author-Date Style

Chicago: Humanities Style

Harvard: Australian Style

Harvard: Author-Date Style

MLA

Vancouver

ISNAD

TIMELINE

LICENCE

SHARE